NASDAQ:IRWD Ironwood Pharmaceuticals - IRWD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $10.44 +0.07 (+0.68%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$10.36▼$10.5750-Day Range$10.37▼$11.8552-Week Range$9.73▼$12.95Volume1.55 million shsAverage Volume2.06 million shsMarket Capitalization$1.61 billionP/E Ratio10.76Dividend YieldN/APrice Target$14.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ironwood Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside40.5% Upside$14.67 Price TargetShort InterestBearish10.72% of Float Sold ShortDividend StrengthN/ASustainability-2.94Upright™ Environmental ScoreNews Sentiment1.32Based on 2 Articles This WeekInsider TradingSelling Shares$2.41 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 starsMedical Sector400th out of 989 stocksPharmaceutical Preparations Industry181st out of 483 stocks 3.3 Analyst's Opinion Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.67, Ironwood Pharmaceuticals has a forecasted upside of 40.5% from its current price of $10.44.Amount of Analyst CoverageIronwood Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.72% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently increased by 1.38%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIronwood Pharmaceuticals has received a 39.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Linaclotide" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ironwood Pharmaceuticals is -2.94. Previous Next 3.0 News and Social Media Coverage News SentimentIronwood Pharmaceuticals has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ironwood Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 10 people have searched for IRWD on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,412,900.00 in company stock.Percentage Held by Insiders13.10% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to remain at $1.05 per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is 10.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.33.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is 10.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 109.86.Price to Book Value per Share RatioIronwood Pharmaceuticals has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ironwood Pharmaceuticals (NASDAQ:IRWD) StockIronwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.Read More Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IRWD Stock News HeadlinesMarch 2, 2023 | finance.yahoo.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Could Be 40% Below Their Intrinsic Value EstimateFebruary 27, 2023 | finance.yahoo.comIronwood Pharmaceuticals to Participate in Upcoming Investor ConferencesMarch 20, 2023 | Investing Daily (Ad)Check Out This 6-Year Win StreakDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. February 20, 2023 | finance.yahoo.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2022 Earnings Call TranscriptFebruary 18, 2023 | seekingalpha.comIronwood Pharmaceuticals, Inc. (IRWD) Q4 2022 Earnings Call TranscriptFebruary 16, 2023 | finance.yahoo.comIronwood Pharmaceuticals (IRWD) Misses Q4 Earnings and Revenue EstimatesFebruary 16, 2023 | finance.yahoo.comIronwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 ResultsFebruary 15, 2023 | msn.comEarnings Outlook For Ironwood PharmaceuticalsMarch 20, 2023 | Investing Daily (Ad)Check Out This 6-Year Win StreakDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. February 15, 2023 | finance.yahoo.comDrug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & OthersFebruary 14, 2023 | finance.yahoo.comIronwood (IRWD) Gets FDA Priority Tag for Linzess sNDAFebruary 13, 2023 | markets.businessinsider.comIronwood Pharma: FDA Grants Priority Review To SNDA For LINZESSFebruary 13, 2023 | finance.yahoo.comIronwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-OldFebruary 10, 2023 | finance.yahoo.com15 Small Innovative Companies According to the MediaFebruary 2, 2023 | finance.yahoo.comIronwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update CallJanuary 16, 2023 | finance.yahoo.comIronwood Pharmaceuticals (NASDAQ:IRWD) shareholders are up 3.7% this past week, but still in the red over the last five yearsJanuary 15, 2023 | seekingalpha.comIronwood Pharmaceuticals (IRWD) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- SlideshowJanuary 9, 2023 | markets.businessinsider.comWhy Ironwood Pharmaceuticals Shares Are Falling During Monday's SessionJanuary 9, 2023 | markets.businessinsider.comIronwood Cuts Annual Outlook Below View; Stock Down In Pre-marketJanuary 9, 2023 | finance.yahoo.comIronwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial GuidanceJanuary 4, 2023 | wsj.comIronwood Pharmaceuticals to Present at the 41(st) Annual J.P. Morgan Healthcare ConferenceJanuary 4, 2023 | finance.yahoo.comIronwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNovember 22, 2022 | finance.yahoo.comIronwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare ConferenceNovember 9, 2022 | finance.yahoo.comIronwood Pharmaceuticals Third Quarter 2022 Earnings: Misses ExpectationsNovember 4, 2022 | finance.yahoo.comIronwood's (IRWD) Q3 Earnings Beat, Linzess Volume GrowsNovember 3, 2022 | msn.comIronwood Pharmaceuticals: Q3 Earnings InsightsNovember 3, 2022 | finance.yahoo.comIronwood Pharmaceuticals (IRWD) Beats Q3 Earnings EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IRWD Company Calendar Last Earnings2/16/2023Today3/20/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IRWD CUSIP46333X10 CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees219Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.67 High Stock Price Forecast$16.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+41.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.97 Trailing P/E Ratio10.69 Forward P/E Ratio9.88 P/E GrowthN/ANet Income$175.07 million Net Margins42.64% Pretax Margin61.48% Return on Equity30.49% Return on Assets16.66% Debt Debt-to-Equity RatioN/A Current Ratio30.58 Quick Ratio30.58 Sales & Book Value Annual Sales$410.60 million Price / Sales3.89 Cash Flow$1.14 per share Price / Cash Flow9.06 Book Value$4.24 per share Price / Book2.45Miscellaneous Outstanding Shares154,160,000Free Float133,963,000Market Cap$1.60 billion OptionableOptionable Beta0.94 Key ExecutivesThomas A. McCourtPresident, Chief Executive Officer & DirectorJason RickardChief Operating Officer & Senior Vice PresidentSravan Kumar EmanyChief Financial Officer & Senior Vice PresidentMarcel MoulaisonVice President-Technical OperationsMichael ShetzlineChief Medical Officer, Senior VP, Head-R&DKey CompetitorsDynavax TechnologiesNASDAQ:DVAXLigand PharmaceuticalsNASDAQ:LGNDMannKindNASDAQ:MNKDOPKO HealthNASDAQ:OPKGeronNASDAQ:GERNView All CompetitorsInsiders & InstitutionsThomas A MccourtSold 33,756 sharesTotal: $378,742.32 ($11.22/share)Thomas A MccourtSold 30,004 sharesTotal: $342,345.64 ($11.41/share)Jason RickardSold 16,746 sharesTotal: $191,071.86 ($11.41/share)Michael ShetzlineSold 9,468 sharesTotal: $108,029.88 ($11.41/share)Ronald SilverSold 2,929 sharesTotal: $33,419.89 ($11.41/share)View All Insider TransactionsView All Institutional Transactions IRWD Stock - Frequently Asked Questions Should I buy or sell Ironwood Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRWD shares. View IRWD analyst ratings or view top-rated stocks. What is Ironwood Pharmaceuticals' stock price forecast for 2023? 3 Wall Street analysts have issued 12 month price targets for Ironwood Pharmaceuticals' stock. Their IRWD share price forecasts range from $13.00 to $16.00. On average, they expect the company's stock price to reach $14.67 in the next twelve months. This suggests a possible upside of 39.8% from the stock's current price. View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts. How have IRWD shares performed in 2023? Ironwood Pharmaceuticals' stock was trading at $12.39 at the beginning of the year. Since then, IRWD stock has decreased by 15.3% and is now trading at $10.49. View the best growth stocks for 2023 here. When is Ironwood Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our IRWD earnings forecast. How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its quarterly earnings results on Thursday, February, 16th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by $0.01. The biotechnology company earned $107.20 million during the quarter, compared to analysts' expectations of $108.23 million. Ironwood Pharmaceuticals had a trailing twelve-month return on equity of 30.49% and a net margin of 42.64%. The company's quarterly revenue was down 8.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.27 EPS. What ETFs hold Ironwood Pharmaceuticals' stock? ETFs with the largest weight of Ironwood Pharmaceuticals (NASDAQ:IRWD) stock in their portfolio include First Trust Nasdaq Pharmaceuticals ETF (FTXH), LeaderShares Activist Leaders ETF (ACTV), Invesco Dynamic Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows 100 ETF (CALF), ETC 6 Meridian Small Cap Equity ETF (SIXS) and SPDR S&P Biotech ETF (XBI). What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings? Ironwood Pharmaceuticals updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $420.00 million-$435.00 million, compared to the consensus revenue estimate of $426.76 million. What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO? 7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX). What is Ironwood Pharmaceuticals' stock symbol? Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD." Who are Ironwood Pharmaceuticals' major shareholders? Ironwood Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include LSV Asset Management (5.17%), Renaissance Technologies LLC (2.85%), Millennium Management LLC (2.60%), Dimensional Fund Advisors LP (2.39%), Victory Capital Management Inc. (1.88%) and Geode Capital Management LLC (1.64%). Insiders that own company stock include Alexander J Denner, Andrew Davis, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Marla L Kessler, Michael Shetzline, Ronald Silver, Thomas A Mccourt and Timothy M O'reilly. View institutional ownership trends. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ironwood Pharmaceuticals' stock price today? One share of IRWD stock can currently be purchased for approximately $10.49. How much money does Ironwood Pharmaceuticals make? Ironwood Pharmaceuticals (NASDAQ:IRWD) has a market capitalization of $1.62 billion and generates $410.60 million in revenue each year. The biotechnology company earns $175.07 million in net income (profit) each year or $0.97 on an earnings per share basis. How many employees does Ironwood Pharmaceuticals have? The company employs 219 workers across the globe. How can I contact Ironwood Pharmaceuticals? Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The official website for the company is www.ironwoodpharma.com. The biotechnology company can be reached via phone at (617) 621-7722, via email at mkaya@ironwoodpharma.com, or via fax at 617-494-0480. This page (NASDAQ:IRWD) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.